Genmab — November 2020
-
-
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) A/S on Thursday, setting a price target of $45
-
ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease https://ceo.ca/@newswire/immunoprecise-and-genmab-enter-into-a-technology-partnership
-
@E L the link is broken
-
And by the way you soon need a 3rd hand when counting GEN1046 expansion
-
Thx
-
AbbVie "So, Genmab, as an example, that filled the gap in hematological oncology that we had. And we wanted an important asset that could cover more areas of hem/onc to continue to drive our leadership position. So, we strategically went out and looked for a CD3xCD20." https://seekingalpha.com/article/4390402-abbvie-inc-abbv-presents-wolfe-research-healthcare-conference-transcript
-
God morgen.
-
USA Luk: Dow Jones 0,2 prosent
S&P 500 opp 0,4 prosent
Nasdaq Composite 0,9 prosent -
Fredagens aviser med Danske Bank, Mærsk og Vestas: https://www.proinvestor.com/investornyt/669779/fredagens-aviser-med-danske-bank-maersk-og-vestas
-
https://ascopost.com/issues/november-25-2020-supplement-hematologic-oncology-almanac/bispecific-antibodies-poised-to-impact-treatment-of-lymphoma-and-other-blood-cancers/ Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind